Every 8-K that AVITA MED INC CDI (AVHHL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVHHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVHHL filings page.
AVITA Medical, Inc. entered into a Global Amendment with Stedical Scientific, Inc. on August 5, 2026, modifying their distribution and manufacturing arrangements for PermeaDerm. AVITA will pay a $500,000 fee for a right of first offer and refusal to expand its exclusive distribution territory to all or part of the European Union, the United Kingdom, and/or Australia.
AVITA’s revenue share from PermeaDerm sales will rise to 67% for sheet products, with higher sharing if AVITA’s gross margin exceeds 50%, and to 80% for glove products, with higher sharing if gross margin exceeds 35%. For 2026, AVITA must achieve total PermeaDerm revenue sharing payments of $1.0 million, with 20% minimum annual growth in such payments through 2030, while all prior minimum revenue sharing requirements are waived.
Stedical may commercialize PermeaDerm in certain U.S. markets not served by AVITA, purchasing product at a 10% premium to AVITA’s actual manufacturing costs. For PermeaDerm sold by Stedical outside the U.S., primarily in Asia, AVITA will charge $200 per carton plus a 10% manufacturing fee, subject to a reasonable volume cap.
AVITA Medical, Inc. disclosed its decision on how often to seek stockholder advisory approval of executive compensation following its June 3, 2026 annual meeting. Stockholders supported holding say-on-pay votes every year, with 9,545,151 votes for 1 year, 924,743 for 2 years, 650,252 for 3 years, 581,759 abstentions, and 3,890,542 broker non-votes.
Consistent with this outcome and the board’s recommendation, the board determined that AVITA Medical will hold future advisory votes on named executive officer compensation every year until the next required frequency vote, which will occur no later than the company’s 2032 annual meeting of stockholders.
AVITA Medical reported Q2 2026 net revenue of $21.7 million, up 18% year over year and 13% sequential, driven by RECELL, Cohealyx, PermeaDerm, and international sales. Gross profit margin was 81.9%, while operating expenses fell 6% to $24.6 million, narrowing the net loss to $7.7 million, or $0.25 per share.
Net cash used declined to approximately $3.2 million, with cash, cash equivalents, and marketable securities of about $11.1 million at quarter end. Management raised 2026 net revenue guidance to $86–$89 million versus $71.6 million in 2025 and expects cash flow breakeven in Q4 2026. The balance sheet shows total liabilities of $75.6 million exceeding assets of $47.8 million, resulting in a stockholders’ equity deficit of $27.8 million. CMS also released proposed 2027 Medicare payment updates that would establish national physician payment and higher facility rates for RECELL if finalized.
AVITA Medical reported first quarter 2026 revenue of approximately $19.3 million, up 4% year-over-year and about 10% sequentially, driven by Cohealyx and improved RECELL utilization as reimbursement normalizes. Gross profit margin was 81.7%, while operating expenses fell 11% to $24.5 million following cost optimization initiatives.
The company recorded a net loss of $10.6 million, or $0.35 per share, improving from a $13.9 million loss, or $0.53 per share, a year earlier. AVITA ended the quarter with $14.3 million in cash and marketable securities and net cash use of about $9.9 million, which management expects to decrease significantly in the second quarter.
The company reaffirmed full-year 2026 revenue guidance of $80 million to $85 million, implying growth of roughly 12% to 19% over 2025. AVITA also highlighted a 10-year BARDA agreement valued at up to $25.5 million, positive interim Cohealyx I clinical data, and new RECELL GO clearance in Australia and New Zealand.
AVITA Medical, Inc. appointed longtime healthcare executive Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. He remains on the Board as an executive director, while Jan Stern Reed has been elected Chair of the Board.
Under a new employment agreement, Mr. Vance receives a base salary of $702,000, an annual bonus target of 80% of salary, and equity awards with cash values of $2,529,000 and $825,000, subject to shareholder approval at the 2027 Annual Meeting. The equity vests over three years in equal annual installments.
If the company terminates him without cause or he resigns for good reason, Mr. Vance is eligible for severance equal to a prorated annual bonus, 18 months of base salary, and 18 months of COBRA premium reimbursement, conditioned on signing a release. The company also confirmed these governance changes in an accompanying press release.
AVITA Medical reported fourth quarter 2025 revenue of $17.6 million, down slightly from $18.4 million a year earlier, as reimbursement headwinds continued to weigh on sales. Gross margin was 81.2%, below the prior year, but operating expenses fell to $24.7 million, helping keep the quarterly net loss flat at $11.6 million.
For full-year 2025, revenue grew about 11% to $71.6 million, while the net loss narrowed to $48.6 million from $61.8 million as the company cut sales, marketing, and administrative costs. AVITA ended 2025 with $18.2 million in cash and marketable securities and subsequently closed a five-year credit facility of up to $60 million, using initial proceeds to refinance debt. For 2026, it expects revenue of $80–$85 million, roughly 12–19% growth, supported by improved Medicare payment rates and advancing clinical studies.
AVITA Medical, Inc. entered into a new five-year senior secured credit facility of up to $60 million with Perceptive Credit Holdings V, LP. The company drew an initial $50 million on closing and used it to fully repay and terminate its prior credit agreement with an affiliate of OrbiMed Advisors.
The loan bears interest at the SOFR rate (with a minimum of 4.00%) plus 7.50%, and includes prepayment premiums of 1% to 10%, an exit fee in certain circumstances, and customary events of default and covenants. AVITA must maintain minimum trailing twelve-month net revenue levels and at least $5 million of unrestricted cash.
As part of the financing, AVITA agreed to issue a 10-year warrant to purchase up to 500,000 shares of common stock, with an additional 150,000 shares becoming issuable if the additional loan commitment is drawn. The warrant’s exercise price is based on the 10-day volume-weighted average price and is subject to shareholder approval and Australian Securities Exchange requirements. AVITA also furnished a press release updating expected fourth quarter and full-year 2025 revenue and providing 2026 revenue guidance.
AVITA Medical, Inc. appointed experienced healthcare executive Joe Woody to its Board of Directors, effective January 1, 2026, to serve until the 2026 Annual Meeting of Stockholders. He will sit on each of the Board’s committees and has been determined to be an independent director under applicable standards. The company states that he has no appointment-related arrangements, family relationships with directors or executives, or material related-party transactions requiring disclosure.
Woody brings more than two decades of medical technology leadership, including serving as CEO of Avanos Medical and President and CEO of Acelity Holdings, as well as senior roles at Covidien and Smith & Nephew and long-term service on the AdvaMed board. Under an offer letter effective January 1, 2026, he will receive $92,500 in annual cash compensation for Board service and an initial equity grant valued at $210,000, with about 30% in stock options and 70% in restricted stock units, plus eligibility for annual equity grants, all subject to shareholder approval.
AVITA Medical (RCEL) amended its credit agreement with affiliates of OrbiMed Advisors, LLC. The Sixth Amendment sets a trailing 12‑month revenue covenant of $70.0 million for the quarter ending December 31, 2025, while keeping subsequent revenue covenants in place through the Maturity Date.
The lenders also waived a requirement that AVITA’s Form 10‑Q for the quarter ended September 30, 2025 contain no “going concern” or similar qualification. In exchange, AVITA agreed to add $500,000 to the principal balance of the Credit Agreement, with interest on this amount accruing as of November 1, 2025 and payable with the original $40,000,000 principal at maturity or earlier repayment.
Separately, AVITA announced it issued a press release covering third‑quarter results for the period ended September 30, 2025.
AVITA Medical (RCEL) announced leadership changes. Effective October 16, 2025, James Corbett departed as Chief Executive Officer and director; the company stated his departure was not due to any disagreement regarding operations, policies, or practices. The Board appointed Chairman Cary Vance as Interim CEO, and named Jan Reed as Lead Independent Director.
Vance brings nearly 30 years of healthcare leadership experience, including CEO roles at PhotoniCare, Titan Medical, and others. As Interim CEO, he will receive an annual base salary of $702,000 and a guaranteed bonus of $140,000 for fiscal 2025. For fiscal 2026, he is eligible for a target bonus equal to 80% of base salary, with half guaranteed and half tied to performance metrics, subject to continued service through the one-year anniversary of the effective date. He will forgo Board compensation while serving as Interim CEO and will be reimbursed for commuting expenses per company policy.